UY33788A - Derivados de arilsulfonamida para la prevención o el tratamiento de trastornos oftalmológicos específicos - Google Patents

Derivados de arilsulfonamida para la prevención o el tratamiento de trastornos oftalmológicos específicos

Info

Publication number
UY33788A
UY33788A UY0001033788A UY33788A UY33788A UY 33788 A UY33788 A UY 33788A UY 0001033788 A UY0001033788 A UY 0001033788A UY 33788 A UY33788 A UY 33788A UY 33788 A UY33788 A UY 33788A
Authority
UY
Uruguay
Prior art keywords
derivatives
arilsulfonamide
prevention
treatment
specific
Prior art date
Application number
UY0001033788A
Other languages
English (en)
Inventor
Belichard Pierre
Pruneau Didier
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of UY33788A publication Critical patent/UY33788A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se dirige al uso terapéutico de derivados de arilsulfonamida.
UY0001033788A 2010-12-09 2011-12-09 Derivados de arilsulfonamida para la prevención o el tratamiento de trastornos oftalmológicos específicos UY33788A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10306381 2010-12-09

Publications (1)

Publication Number Publication Date
UY33788A true UY33788A (es) 2012-07-31

Family

ID=43567690

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033788A UY33788A (es) 2010-12-09 2011-12-09 Derivados de arilsulfonamida para la prevención o el tratamiento de trastornos oftalmológicos específicos

Country Status (15)

Country Link
US (1) US20130315903A1 (es)
EP (1) EP2648712B1 (es)
JP (1) JP2013544871A (es)
CN (1) CN103402507B (es)
AR (1) AR084194A1 (es)
AU (1) AU2011340494B2 (es)
BR (1) BR112013014379A2 (es)
CA (1) CA2820124A1 (es)
ES (1) ES2559223T3 (es)
HK (1) HK1186383A1 (es)
MX (1) MX2013006527A (es)
RU (1) RU2583929C2 (es)
UY (1) UY33788A (es)
WO (1) WO2012076685A1 (es)
ZA (1) ZA201304121B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199801665T2 (xx) * 1996-02-26 1998-12-21 Advanced Research & Technology Institute Makular �demin engellenmesi i�in karbonik anhidraz inhibit�rlerinin kullan�m�.
FR2840897B1 (fr) * 2002-06-14 2004-09-10 Fournier Lab Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
US20080153819A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
TNSN08110A1 (en) * 2008-03-11 2009-07-14 Rekik Raouf Dr Drug delivery to the anterior and posterior segment of the eye from drops
RU2393824C1 (ru) * 2009-04-14 2010-07-10 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ лечения макулярных отеков различного генеза
AR084193A1 (es) * 2010-12-09 2013-04-24 Fovea Pharmaceuticals Dosificaciones de derivados de arilsufonamida

Also Published As

Publication number Publication date
AU2011340494A1 (en) 2013-05-02
RU2013131281A (ru) 2015-01-20
US20130315903A1 (en) 2013-11-28
EP2648712A1 (en) 2013-10-16
ES2559223T3 (es) 2016-02-11
JP2013544871A (ja) 2013-12-19
HK1186383A1 (en) 2014-03-14
EP2648712B1 (en) 2015-10-21
CN103402507B (zh) 2016-02-17
CA2820124A1 (en) 2012-06-14
RU2583929C2 (ru) 2016-05-10
AU2011340494B2 (en) 2015-05-14
ZA201304121B (en) 2014-08-27
BR112013014379A2 (pt) 2016-09-27
CN103402507A (zh) 2013-11-20
MX2013006527A (es) 2014-06-11
WO2012076685A1 (en) 2012-06-14
AR084194A1 (es) 2013-04-24

Similar Documents

Publication Publication Date Title
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
BR112013015859A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
MX2014005304A (es) Biaril eter sulfonamidas y su uso como agentes terapeuticos.
ECSP12012310A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
SMT201200017B (it) Nuovi antagonisti P2X7R e il loro uso.
EA201491854A1 (ru) Асимметрический синтез соединений спирооксиндола, полезных в качестве терапевтических средств
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
BR112013015877A2 (pt) composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
BR112012032721A2 (pt) compostos heterocíclicos, sua preparação e sua aplicação terapêutica
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
UY35746A (es) Derivados de fenilalanina sustituidos
UY35745A (es) Derivados sustituidos de fenilalanina
BR112012015386B8 (pt) composição oftálmica tópica
TR201004464A2 (tr) Kemik erimesi için formülasyon.
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
EA201390398A1 (ru) Арилсульфонамиды для лечения заболеваний цнс
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
PH12015501210A1 (en) Use of pidotimod to treat psoriasis
BR112014022687A8 (pt) uso de uma quantidade eficaz de r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo, composição farmacêutica, r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo